Premium
Spontaneous Nasal Septal Perforation With Antiangiogenic Bevacizumab Therapy
Author(s) -
Burkart Collin M.,
Grisel Jedidiah J.,
Hom David B.
Publication year - 2008
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/mlg.0b013e31817c4296
Subject(s) - medicine , bevacizumab , perforation , nasal septum , surgery , etiology , nose , chemotherapy , materials science , punching , metallurgy
Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies. This case describes a 52‐year‐old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment. Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis. The patient was ultimately treated with a nasal septal button with good symptom relief. This case documents the first report in the otolaryngology literature describing this new etiology for nasal septal perforations.